The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evaluating molecular alteration profiles to distinguish intraductal carcinoma of the prostate.
 
Harshitha Dudipala
No Relationships to Disclose
 
Shayan Nazari
Employment - Caris Life Sciences
Stock and Other Ownership Interests - Caris Life Sciences
Travel, Accommodations, Expenses - Caris Life Sciences
 
Isabela Werneck da Cunha
No Relationships to Disclose
 
Shuanzeng Wei
Consulting or Advisory Role - Caris Life Sciences
 
Andrew Elliott
Employment - Caris Life Sciences
 
Yasmine Baca
Employment - Caris Life Sciences
 
Norm Smith
Employment - Caris Life Sciences
 
Daniel Geynisman
Honoraria - Targeted Oncology
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Exelixis; Merck; Pfizer; Seattle Genetics/Astellas
Research Funding - Arvinas (Inst); Astellas Pharma (Inst); CG Oncology (Inst); Harpoon therapeutics (Inst); Merck (Inst)
 
Jacqueline Brown
Consulting or Advisory Role - Exelixis; Xencor
Research Funding - Hookipa Pharma (Inst); Medicenna (Inst); Merck (Inst); Surface Oncology (Inst); Xencor (Inst)
 
Kevin Zarrabi
Honoraria - Curio Science; OncLive Clinical Congress Consultants
Consulting or Advisory Role - Astex Pharmaceuticals; Eisai; Exelixis; Johnson & Johnson/Janssen
Research Funding - Amgen (Inst); IDEAYA Biosciences (Inst); Janssen (Inst); Vaccitech (Inst)
 
Neeraj Agarwal
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Exelixis; Pfizer
 
Emmanuel Antonarakis
Consulting or Advisory Role - AADi; AIkido Pharma; Amgen; AstraZeneca; Bayer (Inst); Blue Earth Diagnostics; Corcept Therapeutics; Curium Pharma; Foundation Medicine; Hookipa Pharma; Janssen Biotech; Lilly; Menarini Silicon Biosystems; Merck; Pfizer; Sanofi; Tango Therapeutics; Tempus; Z-Alpha
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Macrogenics (Inst); Merck (Inst); Orion Health (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor of a biomarker technology that has been licensed to Qiagen
 
Daniel Herchenhorn
Consulting or Advisory Role - Adium Pharma; Astellas Pharma; AstraZeneca; Bayer; Janssen-Cilag; MSD Oncology
 
Rana McKay
Consulting or Advisory Role - Ambrx; Ambrx; Arcus Biosciences; Astellas Medivation; AstraZeneca; AVEO; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb; Calithera Biosciences; Caris Life Sciences; Dendreon; Esiai; Exelixis; Janssen; Lilly; Merck; Myovant Sciences; NeoMorph; Novartis; Pfizer; Sanofi; Seagen; Sorrento Therapeutics; Sumitomo Pharma Oncology; Telix Pharmaceuticals; Tempus; Vividion Therapeutics
Research Funding - Artera (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Exelixis (Inst); Oncternal Therapeutics (Inst); Tempus (Inst)